We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Chicago, IL – December 9, 2022 – Zacks Market Edge is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here:
Every week, host and Zacks stock strategist, Tracey Ryniec, will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life.
This week, Tracey is joined by Zacks Chief Equity Strategist, and economist, John Blank, to talk about their favorite end of the year topic: will the US economy be in recession next year?
In 2022, with the Fed raising rates aggressively and many of the recession indicators flashing red, many believe that a recession is inevitable in 2023. But is it?
Tracey and John again look at the important economic data, including the jobs data. One thing that is clear, is that the US economy is currently not in a recession, despite many in the media harping that it is. The US is averaging monthly payroll gains of 392,000 in 2022 through November.
And the weekly jobless claims data has yet to show much slowing.
Where Should You Invest in 2023?
If a recession IS coming next year, where should an investor be hiding out?
The drug stocks have been popular with investors over the last few years due to the pandemic.
Eli Lilly shares are up 32% year-to-date and are breaking out to new 5-year highs. However, analysts have been cutting earnings estimates at Eli Lilly recently. Earnings are expected to fall 4.7% in 2022.
Eli Lilly may be popular with investors, but it’s not cheap. It is trading with a forward P/E of 47.
However, the reverse is true of Pfizer. Pfizer is dirt cheap, with a forward P/E of 7.9 but shares have also fallen 17% this year.
While Pfizer earnings are expected to be up 46% in 2022, analysts expect them to fall 25% in 2023.
Are Eli Lilly and Pfizer the wrong place to be in 2023?
With the Fed raising rates, you’d think that banks like JPMorgan Chase would be a place to hide out in this year, and next.
Shares of JPMorgan Chase are down 17% year-to-date, which is mostly in line with the S&P 500, but they have rallied 15% in the last 3 months. John owns JPMorgan Chase in his Large Cap Trader portfolio at Zacks.
Yet shares of this big bank are cheap, with a forward P/E of 11.2. JPMorgan Chase also pays a dividend, yielding 3%.
Ulta Beauty is an American beauty retailer, with both brick and mortar and online sales. Beauty has been hot in 2022, even with inflation, because there are many ways customers can trade down, if necessary.
However, both prestige and drugstore make-up are doing well this year as people attend events and experiences like weddings and prom.
Ulta shares have bucked the negative trend in 2022. They are up 16.4% year-to-date and are at 5-year highs.
But Ulta isn’t cheap. It trades with a forward P/E of 20.5.
Is the Ulta rally nearing an end or there still time to get in in 2023?
John believes in buying some of the beaten down ETFs for next year, including the Invesco QQQ ETF, which is simply known as the QQQ. It tracks the NASDAQ.
The QQQ is down nearly 30% year-to-date. John believes investors should be dollar-cost-averaging into it next year.
QQQ pays a dividend, yielding 0.7%. It has an expense ratio of 0.2%.
Are you brave enough to buy the QQQ in 2023?
What Else Do You Need to Know About the Possible Recession Next Year?
Listen to this week’s podcast to find out.
[In full disclosure, Tracey owns shares of ULTA in her own personal portfolio.]
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zacks Market Edge Highlights: LLY, PFE, JPM, ULTA, QQQ
For Immediate Release
Chicago, IL – December 9, 2022 – Zacks Market Edge is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here:
https://www.zacks.com/stock/news/2026974/will-there-be-a-recession-in-2023
Will There Be a Recession in 2023?
Welcome to Episode #340 of the Zacks Market Edge Podcast.
Every week, host and Zacks stock strategist, Tracey Ryniec, will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life.
This week, Tracey is joined by Zacks Chief Equity Strategist, and economist, John Blank, to talk about their favorite end of the year topic: will the US economy be in recession next year?
In 2022, with the Fed raising rates aggressively and many of the recession indicators flashing red, many believe that a recession is inevitable in 2023. But is it?
Tracey and John again look at the important economic data, including the jobs data. One thing that is clear, is that the US economy is currently not in a recession, despite many in the media harping that it is. The US is averaging monthly payroll gains of 392,000 in 2022 through November.
And the weekly jobless claims data has yet to show much slowing.
Where Should You Invest in 2023?
If a recession IS coming next year, where should an investor be hiding out?
1. Eli Lilly (LLY - Free Report) and Pfizer (PFE - Free Report)
The drug stocks have been popular with investors over the last few years due to the pandemic.
Eli Lilly shares are up 32% year-to-date and are breaking out to new 5-year highs. However, analysts have been cutting earnings estimates at Eli Lilly recently. Earnings are expected to fall 4.7% in 2022.
Eli Lilly may be popular with investors, but it’s not cheap. It is trading with a forward P/E of 47.
However, the reverse is true of Pfizer. Pfizer is dirt cheap, with a forward P/E of 7.9 but shares have also fallen 17% this year.
While Pfizer earnings are expected to be up 46% in 2022, analysts expect them to fall 25% in 2023.
Are Eli Lilly and Pfizer the wrong place to be in 2023?
2. JPMorgan Chase (JPM - Free Report)
With the Fed raising rates, you’d think that banks like JPMorgan Chase would be a place to hide out in this year, and next.
Shares of JPMorgan Chase are down 17% year-to-date, which is mostly in line with the S&P 500, but they have rallied 15% in the last 3 months. John owns JPMorgan Chase in his Large Cap Trader portfolio at Zacks.
Yet shares of this big bank are cheap, with a forward P/E of 11.2. JPMorgan Chase also pays a dividend, yielding 3%.
Is JPMorgan Chase a deal?
3. Ulta Beauty (ULTA - Free Report)
Ulta Beauty is an American beauty retailer, with both brick and mortar and online sales. Beauty has been hot in 2022, even with inflation, because there are many ways customers can trade down, if necessary.
However, both prestige and drugstore make-up are doing well this year as people attend events and experiences like weddings and prom.
Ulta shares have bucked the negative trend in 2022. They are up 16.4% year-to-date and are at 5-year highs.
But Ulta isn’t cheap. It trades with a forward P/E of 20.5.
Is the Ulta rally nearing an end or there still time to get in in 2023?
4. Invesco QQQ ETF (QQQ - Free Report)
John believes in buying some of the beaten down ETFs for next year, including the Invesco QQQ ETF, which is simply known as the QQQ. It tracks the NASDAQ.
The QQQ is down nearly 30% year-to-date. John believes investors should be dollar-cost-averaging into it next year.
QQQ pays a dividend, yielding 0.7%. It has an expense ratio of 0.2%.
Are you brave enough to buy the QQQ in 2023?
What Else Do You Need to Know About the Possible Recession Next Year?
Listen to this week’s podcast to find out.
[In full disclosure, Tracey owns shares of ULTA in her own personal portfolio.]
See these time-sensitive tickers now >>
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch/
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/performance
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.